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Summary
Progressive multifocal leukoencephalopathy (PML) is a
serious opportunistic infection of the brain caused by the
JC polyomavirus (JCPyV). PML occurs when immune
control of persistent infection with JCPyV fails, the virus
mutates and changes its cellular tropism, enters the brain
and infects astrocytes, oligodendrocytes and, in particular
cases, also neurones. Currently, there is no therapy for
this often fatal disease. A number of approaches have
failed, and only the restoration of protective immunity, if
possible, can lead to clearance of the virus once PML
has occurred. During the last two decades, investigators
have attempted to understand the factors contributing to
the development of PML, which immune mechanisms are
involved in immune surveillance, and which in clearing
JCPyV from the brain once PML has occurred. Recent da-
ta suggest that both CD4+ and CD8+ T cells of the cellular
immune system, and also JCPyV-specific antibodies, are
involved in protection against PML and in resolving the op-
portunistic infection. Based on the current immunological
data, prophylactic and therapeutic vaccination strategies
have been proposed, and first treatment attempts in PML
patients have provided promising results that indicate ther-
apeutic vaccination may be feasible.
Key words: JC polyomavirus, progressive multifocal
leukoencephalopathy (PML), active and passive vaccina-
tion
Introduction
The clinical disease entity progressive multifocal leukoen-
cephalopathy (PML) was first described in 1959 [1], and
in 1971 the polyomavirus JC (JCPyV) was identified as
the pathogen that causes it [2]. Characteristics of PML
include an underlying hereditary or acquired compromise
of immune function, particularly following treatment with
immunomodulatory/immunosuppressive agents or human
immunodeficiency virus (HIV) infection [3, 4]. A wide
range of conditions have been described as potential rea-
sons for the immunocompromise that may lead to PML.
These include: immunodeficiencies such as CD4+ lym-
phopenia and hyper-immunoglobulin E (hyper-IgE) syn-
drome; broad-spectrum immunosuppressive treatment;
highly specific immunomodulatory drugs such as anti-
CD20 (rituximab) and anti-VLA4 (natalizumab) specific
monoclonal antibodies; infections (HIV); organ transplan-
tation; and autoimmune/inflammatory diseases such as sar-
coidosis, rheumatoid arthritis or systemic lupus erythe-
matosus. The breadth of these conditions indicates that im-
mune control of JCPyV probably involves several aspects
of adaptive immunity. Infection with JCPyV is widespread,
and approximately 60 to 70% of the world's population is
infected. In the immunologically healthy individual, the in-
fection remains persistent throughout life in the kidney and
urinary tract [5]. Whether JCPyV can also establish per-
sistent infection in other organs and tissues, including the
brain, is currently not clear.
Compromised immune control may lead to mutations of
the archetypic or wild type (wt) strain of JCPyV to types
with rearranged regulatory regions and mutations in the
major capsid protein JCPyV VP1. Both are probably rele-
vant for the switch of the cell tropism to glial cells and neu-
rones [6–9]. In the immunocompromised host, PML caus-
es a lytic infection of oligodendrocytes and morphological
changes of astrocytes in the absence of an inflammatory re-
sponse. Once immune function is restored, e.g., following
antiretroviral therapy in the case of HIV, adaptive immune
mechanisms lead to an inflammation in the area of the
PML lesion, which is referred to as immune reconstitution
inflammatory syndrome (IRIS) [3, 4, 10–12]. Although the
immune mechanisms underlying IRIS mediate the elimi-
nation of JCPyV from the brain, the resulting inflamma-
tion can cause additional brain damage and may lead to the
death of the patient [11, 12]. Nevertheless, restoration of
immunity is, to date, the only way to eliminate the virus
from the brain and to thereby halt PML. Several poten-
tial alternative treatments of PML that looked promising,
e.g. with respect to preventing viral entry into glial cells
by receptor-blocking drugs, failed [13]. Both cellular and
humoral immune components were found to be important
players during IRIS in PML lesions [14]. These findings
provided the rationale for vaccination approaches against
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PML [15]. In parallel to a decline of PML frequency in
HIV-infected individuals, there has been an increase asso-
ciated with therapy with certain biologics, particularly with
anti-CD20 treatment in haematopoietic malignancies and
autoimmune diseases, and anti-VLA4 treatment in multi-
ple sclerosis (MS) [4, 16].
In this review, we will summarise the types of immunod-
eficiencies leading to PML and give our outlook on fu-
ture strategies towards the development of prophylactic
and therapeutic approaches for PML.
Development of PML
JCPyV is a small ubiquitous DNA virus with six open
reading frames under the control of a regulatory non-cod-
ing region [2]. The major capsid protein VP1 can self-as-
semble into virus-like particles (VLPs) consisting of 72
pentamers of VP1 [17]. The high anti-JCPyV antibody
seroprevalence of up to 60% in healthy individuals indi-
cates widespread infection with JCPyV [5]. In the healthy
host, JCPyV persists in urothelial cells and is shed into the
urine in 50% of individuals. The infection remains clini-
cally invisible throughout life [4]. JCPyV can also estab-
lish latency in haematopoietic progenitor cells, which may
mobilise under conditions of immunocompromise or im-
munomodulation from the bone marrow niche into the pe-
ripheral circulation [18, 19]. How JCPyV finally enters
the central nervous system (CNS) is currently not entirely
clear. B cells have been suggested as viral carriers into the
CNS [18–20], but the fact that empty VLPs can enter the
CNS compartment indicates that free virus may be able to
cross the blood brain barrier [21]. JCPyV DNA fragments
and proteins have been detected repeatedly in 13 to 50% of
non-PML brain biopsies [22–24], which led to speculation
that JCPyV may reach the brain and may persist at this site
in a latent state without causing PML. In order to avoid po-
tential contamination of brain biopsies with B cells from
the peripheral circulation, some research groups used laser
capture microdissection and detected fragments of JCPyV
DNA in oligodendrocytes, astrocytes and cerebellar granu-
lar cell neurones of non-PML patients [25–27]. Because of
the paucity of data and lack of definitive proof, the hypoth-
esis that reactivation of latent JCPyV infection of the brain
may lead to PML has been intensely debated since.
In PML, JCPyV variants enter the CNS and infect glial
cells. This leads to lysis of oligodendrocytes and swelling
of astrocytes in PML and of neurones in granule cell neu-
ronopathy. In the vast majority of cases, glio-/neurotropic
JCPyV strains isolated from PML patients display both re-
arrangements in the regulatory noncoding control region
and mutations in specific areas of VP1 [7, 8, 28]. In-
terestingly, VP1 mutations were mainly identified in the
three exterior loops of VP1 (fig. 1). In addition to classical
PML, which presents with large multifocal, partly conflu-
ent white matter lesions, JCPyV infection may in some
cases manifest in other regions of the CNS and may there-
by cause distinct JCPyV-associated diseases, including
GCN, JCPyV encephalopathy and possibly also JCPyV
meningitis [6]. In contrast to PML, GCN is characterised
by lytic infection of cerebellar granule cell neurones with
JCPyV, which results in cerebellar atrophy [29]. Although
reports of GCN cases are less frequent, a histopathological
survey reported that JCPyV-infected neurones may also be
found in classical PML [30]. In GCN, the isolated infec-
tion of cerebellar neurones has been linked to mutations
in the C-terminal region of VP1, which are probably in-
volved in the altered tropism for neurones [9]. The glycan
receptor LSTc (sialylneolacto-N-tetraose c) was identified
as functional host receptor of a prototypical JCPyV strain
(MAD1) [31]; however, this binding is abrogated in PML-
associated JCPyV variants [32]. Therefore, the cellular en-
try receptor of JCPyV in glial cells and neurones remains
unknown.
Protection from viral infections and elimination of virus-
infected cells during acute infection involve cellular im-
munity, which is mediated by virus-specific CD4+ helper
T cells and CD8+ cytotoxic T cells, as well as virus-spe-
cific antibodies from B cells. Their relative importance
depends on the respective virus, on its tissue and/or cell
tropism, on the structure of its envelope, on the compo-
sition of virus-encoded immunogenic epitopes and pep-
tides, on the type of release from the infected cell (i.e.
budding from the cell membrane or lytic infection), and
other factors. Several lines of evidence suggest an impor-
tant role of the adaptive immune system to protect the
infected host during an asymptomatic persistent infection
with archetypic JCPyV, as well as in clinically manifest
PML, with infection of the brain with JCPyVPML variants.
Figure 1: JCPyV and the development of PML. JCPyV encodes for six open reading frames under the control of the regulatory noncoding
control region (NCCR) element. Mutations in the three exterior loops of the major capsid protein JCPyV VP1 may in situations of immunocom-
promise lead to an opportunistic infection in the brain, known as PML.
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These pieces of evidence include PML occurrence in states
of immunodeficiency of one or several arms of the adap-
tive immunity, such as hereditary antibody and/or cellular
or acquired cellular immunodeficiencies, including HIV
infection, or immunodeficiencies induced by chemother-
apy, immunomodulatory or -suppressive therapies, allo-
transplantation or certain autoimmune diseases [14] (table
1). As patients with haematological malignancies are fre-
quently treated with chemotherapy and immunosuppres-
sive therapies, it remains difficult to discern if the primary
disorder, the secondary immunosuppression, or both are
critical for PML development.
Types of immunodeficiencies leading to PML
After its first description in 1959 [1], PML was considered
a rare disease that was mainly diagnosed in immunodefi-
cient patients in the era before the emergence of acquired
immunodeficiency syndrome (AIDS) [38]. The number of
PML cases drastically increased with the AIDS pandemic,
and PML became one of the main opportunistic infections
in HIV+ patients and a major cause of death [39] (table 1).
With the introduction of combined highly active antiretro-
viral therapy (HAART), the incidence of PML decreased,
but remains a severe and life-threatening complication for
AIDS patients [40–42].
The use of immunomodulatory therapies for various au-
toimmune diseases has led to an alarming increase of PML
cases among patients with conditions that were previously
not linked to any substantial PML risk. Immunotherapy-
associated PML received broad attention with natalizumab
in patients with MS or Crohn’s disease [16, 43–45]. Na-
talizumab had been approved for the treatment of relaps-
ing-remitting MS (RRMS) in 2004, since it effectively re-
duced CNS inflammation via its inhibition of lymphocyte
migration through the blood-brain barrier [46, 47]. It was
briefly taken off the market after report of the first PML
cases and then reintroduced with a strict safety and risk
monitoring programme. Natalizumab is the immunother-
apy with the highest number (698 as of December 2016)
and highest rate (4.18 per 1000 cases treated) of confirmed
PML cases [48]. Efalizumab is a humanised monoclonal
antibody that was developed for the treatment of psoriasis
by targeting CD11a in order to inhibit lymphocyte acti-
vation and migration [49]. It was voluntarily withdrawn
from the market by the manufacturer after reports of four
efalizumab-associated PML cases [4, 50, 51]. The B cell
depleting monoclonal antibody rituximab is widely used
to treat haematological cancers and autoimmune diseases,
and to avoid graft rejection [52, 53]; although it was ap-
proved as long ago as 1997, rituximab has been associated
with numerous PML cases only in the last 10 years [54].
The direct role of rituximab in PML development is still
debated, since most of the patients suffered from immuno-
suppressed states either because of their primary haema-
tological disorder or because of additional immunosup-
pressants, which made them more vulnerable to develop-
ing PML [54, 55]. Alemtuzumab, a monoclonal antibody
against CD52 used as second-line therapy in MS to de-
plete B and T cells, was clearly linked to PML in some
Table 1: Hereditary and acquired diseases and immunomodulatory/- treatments associated with a risk of PML or other JCPyV-induced CNS infectious diseases.
Category of disease Diseases
Hereditary immune deficiencies
[33]
– Adenosine deaminase deficiency
– CD40 ligand deficiency
– Combined immune deficiency
– Common variable immune deficiency
– DOCK8 (dedicator of cytokinesis 8 protein) deficiency
– Gamma heavy chain disease
– Hyper-IgM syndrome
– Immunodeficiency-centromeric instability-facial dysmorphism syndrome syndrome
– Purine nucleoside phosphorylase deficiency
– Severe combined immune deficiency
– Signal transducer and activator of transcription 1 gain-of-function immune deficiency
– Wiskott-Aldrich syndrome
– X-linked agammaglobulinaemia
– Idiopathic CD4+ lymphopenia*
Acquired immune deficiencies
[18, 34]
– Human immunodefiency infection or acquired immune deficiency syndrome
– Haematopietic stem cell transplantation
– Immunosuppressive therapy in organ transplant recipients
– Haematological malignancies (e.g. lymphomas and leukaemias)
– Immunosuppression during chemotherapy of solid cancers
– Systemic lupus erythematosus
– Sarcoidosis
– Immunosuppressive or -modulatory therapy in autoimmune diseases (rheumatoid arthritis, psoriatic arthritis, psoriasis, juvenile
idiopathic arthritis, inflammatory bowel disease, ankylosing spondylitis, multiple sclerosis)
Immunomodulatory treatments
[4, 18, 35, 36]
– Natalizumab
– Efalizumab
– Belimumab
– Rituximab
– Fingolimod
– Dimethylfumarate
– Alemtuzumab
– Tumour necrosis factor-alpha inhibitors (infliximab, adalimumab, etanercept)
– Ofatumumab
– Mycophenolate mofetil
– Betalacept
– Brentuximab
– Fludarabine
– Ruxolitinib
– Leflunomide
* Heterogeneous disease of unknown aetiology, but a genetic aetiology has been described in some cases [37]
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other diseases, such as leukaemia. So far, no PML cases
have been observed in alemtuzumab-treated MS patients
[56–58], and the same holds true for rituximab-treated MS
patients, in whom there is so far no reported PML case.
Further PML cases were reported with belimumab, a mon-
oclonal antibody targeting the B-cell activating and sur-
vival factor BAFF, used for the treatment of systemic lupus
erythematosus (SLE) [59]. Furthermore, with several tu-
mour necrosis-alpha (TNFα) inhibitors such as adalimum-
ab, infliximab and etanercept, which are currently used to
treat psoriasis, rheumatoid arthritis and other autoimmune
diseases, PML was observed in predisposed patients [60,
61].
For other immunomodulatory drugs such as fingolimod
and dimethyl fumarate used for the treatment of MS or oth-
er autoimmune diseases, only a few PML cases have been
reported [62]. In the fingolimod-treated MS patients, it is
difficult to clearly link this drug with PML since most of
these patients had been treated with natalizumab prior to
fingolimod therapy [63, 64]. The first cases of PML un-
der dimethyl fumarate were reported in psoriasis patients,
but there are now publications of PML also in the context
of MS [65–68]. Multiple PML cases occurred under im-
munosuppressive treatments to avoid allograft rejection or
to treat cancer or autoimmune diseases; however, it is dif-
ficult to discern whether the underlying conditions of im-
munocompromise or the treatment-induced immunosup-
pression are the main cause for PML [69].
Hereditary immunodeficiencies may exclusively or prefer-
entially compromise one specific immune cell type, e.g.,
in idiopathic CD4+ lymphopenia (table 1). Similarly, treat-
ments that have been linked to PML may affect specific
immune cells more profoundly than others. As an example,
natalizumab blocks the entry of CD4+ T cells into the CNS
much more efficiently than that of CD8+ T cells [70]. In
the case of HIV infection, the virus specifically targets
the CD4 receptor and leads to quantitative and qualita-
tive alterations of CD4+ T cells, but each of these condi-
tions also indirectly affects the function of CD8+ T cells
and antibody responses. The occurrence of IRIS, such as
in AIDS patients starting antiretroviral therapy or in natal-
izumab-treated MS patients after washout of natalizumab
by plasmapheresis, indicates restoration of immune func-
tions that leads to an inflammatory response within the
area of the PML lesion [11, 12]. In depth studies of the cel-
lular components of this inflammatory response revealed
a central role of CD4+ T cells in orchestrating an efficient
CD8+ effector T cell response in order to clear the virus
[71–73].
Risk stratification and therapeutic approaches
for PML
Natalizumab has been reapproved with the stipulation that
factors contributing to PML risk must be identified. Stud-
ies of potential risk factors for PML identified prior im-
munosuppression, duration of natalizumab treatment and
presence of anti-JCV antibodies as predisposing factors
and, based on these, a risk classification scheme was pro-
posed [74, 75]. The latter stratification involved monitor-
ing of serum and plasma JCPyV VP1-specific antibod-
ies during natalizumab treatment [75]. Interestingly, when
the JCPyV antibody indices of natalizumab-treated MS pa-
tients were correlated with the incidence rate of PML in
the different strata, patients with a higher antibody index
had a substantially increased risk for developing PML. The
risk stratification protocol ensured a reduction of PML in-
cidence, but also limited the use of this very efficient drug
in MS. Moreover, recent data showed that intrathecal pro-
duction of JCPyV VP1-specific antibodies was enhanced
in patients at time of PML [76]. As another potential risk
marker, Schwab et al. showed that patients had low per-
centages of CD62L+ T cells before they developed PML
[77, 78]. However, these findings are still debated, since
an independent study did not confirm this observation [79].
Furthermore, MS patients with cerebrospinal fluid (CSF)
lipid-specific IgM oligoclonal bands have a lower risk of
developing natalizumab-associated PML than patients
without such bands [80]. It is currently not clear how the
above findings translate into increased risk with respect to
cellular or humoral immune compromise.
Reconstituting the protective immunity or reversing the
immunosuppression is so far the best way to eliminate
JCPyV infection from the CNS and to overcome PML. Im-
mune reconstitution in HIV+ patients can be achieved with
HAART, which in turn will lead to the recovery of CD4+
lymphocytes. HAART has greatly reduced the number of
HIV+ PML cases and significantly improved the survival
of HIV+patients developing PML [3, 40, 41, 81–83]. How-
ever, immune reconstitution in PML can lead to IRIS in
10 to 30% of HIV+ patients, resulting in subacute onset of
sometimes severe neurological deficits, which often per-
sist after recovery from PML [3, 40, 83, 84]. The same ap-
plies to nearly all natalizumab-associated PML patients in
whom natalizumab is discontinued and removed by plasma
exchange after PML diagnosis [12, 85]. IRIS may be care-
fully treated with corticosteroids to ameliorate CNS tissue
destruction by exuberant JCPyV-specific immune response
[86, 87]. Corticosteroid treatment should be tapered slow-
ly to avoid abrogation of the antiviral immune reaction.
Alternatively, the C-C motif chemokine receptor (CCR5)
antagonist maraviroc approved for the treatment of HIV
infection, has been discussed to be useful in preventing
overshooting IRIS [88–90]. Since maraviroc was not help-
ful in other PML cases [91], its therapeutic role for PML-
IRIS prevention or treatment has to be defined in larger
trials. However, it is not always possible to stop immune
suppression, for example in organ transplant patients, in
whom it could lead to graft rejection. Furthermore, some
PML patients may not develop IRIS at all because of per-
sisting severe immunosuppression related to haematologi-
cal malignancy, or treatment with rituximab or alemtuzum-
ab. In these cases, other therapies targeting JCPyV have to
be considered.
Several antiviral drugs intended to target JCPyV have been
investigated in vitro and tested in individual medical treat-
ments or in clinical trials. These drugs target the virus at
different stages of infection by blocking cell entry or viral
replication. JCPyV uses sialylated receptors [31, 92] and
the serotonin receptor 2 (5-HT2) [93, 94] to enter the cells.
Several serotonin receptor antagonists are currently mar-
keted for the treatment of mental disorders and have been
tested as potential therapeutics for PML. Chlorpromazine
efficiently blocked the viral infection in cell-based assays
[94–96], but has never been tested clinically, probably be-
cause of its poor selectivity and the potential side effects.
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Mirtazapine was empirically reported to be beneficial in
several independent PML case studies, but available data
suggest that it is not effective [97–101]. The in vitro in-
hibitory effects of ziprasidone could not be translated into
two PML patients [102], and another study [103] report-
ed a PML case who recovered after risperidone treatment
despite the fact that this drug could not block the attach-
ment and internalisation of JCPyV into primary human fe-
tal glial cells [104].
Another approach to interfering with the life cycle of
JCPyV would be to block viral DNA replication, for exam-
ple, by inhibiting viral DNA polymerases or topoisomeras-
es. Cidofovir, a drug approved for the treatment of human
cytomegalovirus (HCMV) infection, and its prodrug brin-
cidofovir suppressed JCPyV replication in a cell-based as-
say even at a low, non-toxic concentration [105, 106], but
neither improved survival nor neurological status of PML
patients [107, 108]. Cytarabine reduced JCPyV replication
in vitro [109], but failed to demonstrate an improvement
of patients’ prognosis upon treatment [110]. Topotecan, a
chemotherapeutic agent for certain ovarian cancers, inhib-
ited JCPyV DNA replication in glial cells [111]. However,
the results of a clinical study addressing its efficacy were
not convincing, since only a few patients responded to the
therapy and several enrolled patients experienced severe
adverse events [112]. Mefloquine, a medication used to
prevent or treat malaria, was selected as a potential JCPyV
inhibitor in a high-throughput screening of approved drugs
and was shown to block DNA replication after viral entry
[113]. Given the availability and safety of this medicine,
mefloquine was tested in a clinical trial that was prema-
turely terminated after interim data analyses suggested that
the study was unlikely to succeed [114]. The lack of signs
of efficacy for all these antiviral drugs has been disappoint-
ing, in particular after often promising in vitro results. The
difficult translation into patients could be explained by sta-
bility issues, low brain penetration, toxicity issues, lack of
specificity for JCPyV or JCPyV variants, and a cell type-
dependent effect.
With the recent breakthrough in genome editing using the
CRISPR/Cas9 system, two independent groups targeted
functional regions in the JCPyV genome to inhibit viral
replication in infected cells. The first approach aimed to
introduce mutations in the early expressed JCPyV large T
antigen in order to suppress viral replication [115], and an-
other study focused on the modification of the regulatory
noncoding control region element and the major capsid
protein VP1 [116]. In both cases, the infection and spread
of JCPyV could be inhibited in vitro in the JCPyV-permis-
sive glial SVG-A cell line. However, this technique is still
far away from potential clinical use in PML patients, and
its efficacy has to be validated for JCPyV variants and dif-
ferent cell types. Furthermore, it is unclear whether those
constructs can be delivered successfully to the infected cell
types in the CNS and whether such an approach would
have safety issues or even be more hazardous in combina-
tion of rearranged and mutated JCPyV variants.
Immune modulators, such as cytokines, are also used to
treat viral diseases because of their potential antiviral ca-
pacity or ability to augment the immune response against
the pathogen. Type 1 interferons, such as IFN-α, are known
for their antiviral capacity, but failed in an open-label study
in HIV+ PML patients [117], despite a retrospective analy-
sis claiming increased survival times [118]. Interestingly,
the use of lymphoproliferative cytokines, such as inter-
leukin (IL)-2 of the common gamma-chain cytokine fami-
ly, revealed beneficial effects on the response and outcome
in single case studies with PML patients [119–122]. An-
other cytokine of the common gamma-chain family, IL-7,
was also successfully tested in compassionate use alone or
in combination with antiviral drugs [123–125].
On the basis of current immunological data [14], approach-
es to boost specific immunity against JCPyV have also
been explored. Recent studies suggested two novel promis-
ing immunotherapeutic approaches for the treatment or
prevention of PML that are based on active or passive
immunisation specifically targeting JCPyV. The develop-
ment of prophylactic vaccines based on virus-like particles
(VLPs) has been successful in the case of HPV [126], a
nonenveloped DNA virus that shares similar structural el-
ements with JCPyV. The use of VLPs formed by the re-
assembly of JCPyV VP1 proteins appears as a good ap-
proach for an effective vaccine since VLPs represent a
combination of multiple epitopes and structural arrange-
ment that should be optimal for uptake by antigen-pre-
senting cells, in particular JCPyV-specific B cells. Further-
more, the choice of the right adjuvant is essential in order
to efficiently boost the virus-specific immune response. A
vaccine consisting of JCPyV VP1 VLPs in combination
with IL-7 and imiquimod, a toll-like receptor 7 (TLR7) ag-
onist, has been tested in two PML patients, one suffering
from idiopathic CD4+ lymphopenia, the other from breast
cancer, polychemotherapy, autologous and allogeneic bone
marrow transplantation and subsequent graft-versus-host
disease [15]. The treatment was well tolerated and safe,
and several lines of evidence suggested that the immunisa-
tion caused a “therapeutic” immune response: (1) The CSF
JCPyV viral load disappeared, (2) a pronounced prolifera-
tion of VP1-specific CD4+ T cells was observed, (3) mag-
netic resonance imaging studies showed contrast enhance-
ment in the PML lesions as a clear sign of local immune
response and IRIS, and (4) an amelioration of the neuro-
logical deficits was seen [15]. Although immune reconsti-
tution with IL-7 alone has already shown promise in the
management of PML, a combination with VLPs ensured a
specific and robust activation and expansion of VP1-spe-
cific T cells. However, it is at present not clear whether
IL-7 is needed or not in the above vaccination scheme. The
same active vaccination approach was also successfully
administered to a third PML patient with idiopathic CD4+
lymphopenia [127]. Vaccination substantially reduced the
CSF viral load and the progression of PML. The patient al-
so showed a strong rise in neutralising antibodies against
her own mutant JCPyV strain, showing that this vaccine
broadened the humoral response even against JCPyV vari-
ants. The active therapeutic immunisation would be most
suitable for patients with residual and restorable immune
function. We further assume that active prophylactic im-
munisation of healthy individuals or patients under treat-
ments with PML risk has the potential to prevent PML or,
in seronegative individuals, even the establishment of la-
tent/persistent infection altogether.
With respect to possible passive vaccination against PML,
antibody therapy has been successfully applied for various
diseases; broadly neutralising antibodies are promising
candidates for the treatment of viral infection and are cur-
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Figure 2: Overview of the active and passive immunization approaches for the prophylactic and therapeutic treatment of PML. These novel
vaccination approaches are considered for both patients with PML and immunocompromised, JCPyV-positive patients at risk of developing
PML. Passive immunisation involves administering broadly neutralising JCPyV VP1-specific recombinant antibodies. The latter are expected
to provide protection from and neutralisation of neurotropic pathological JCPyV VP1 variants. The active immunisation strategy implies a direct
boost of adaptive immune responses specific for JCPyV variants in patients by vaccinating with whole protein or peptides of the major capsid
protein VP1 in combination with an adjuvant (e.g., imiquimod) and supporting cytokines (e.g.. interleukin-7). The latter will lead particularly to
the activation and expansion of JCPyV-specific CD4+ effector T cells and antibody-producing B cells, which will confer a broad protection from
pathological JCPyV infection to the patients.
rently in development for numerous pathogens, such as
influenza, respiratory syncytial, Ebola and Zika viruses
[128–132]. The above data indicate that an effective hu-
moral response is important for controlling JCPyV infec-
tion and/or eliminating virus from the brain in PML. Ev-
idence includes reports that HIV+ PML survivors showed
higher IgG titres compared with controls [133], that B cells
and plasma cells infiltrate the brain during IRIS [71, 134],
that intrathecal production of JCPyV-specific antibodies
increases with onset of IRIS [76, 135], that hereditary im-
munodeficiencies affecting B cells or antibodies can cause
PML [136, 137] and that immunomodulatory drugs target-
ing B cells may lead to PML [4, 138]. The level of JCPyV
VP1-specific antibodies is usually measured to stratify the
patients at risk of developing PML, but this test does not
discriminate between archetype JCPyV and PML-associat-
ed mutants. Further, there seems to be no correlation be-
tween the level of anti-JCPyV antibodies and their neutral-
ising activity in the sera of MS patients [139]. Why higher
anti-JCPyV antibody titres in natalizumab-treated MS pa-
tients are related to higher risk is at present not clear. We
demonstrated that the humoral immune response against
JCPyV mutants was compromised in natalizumab-associ-
ated PML patients, and that immune reconstitution led to
a broadened antibody response against the PML-associat-
ed JCPyV variants [135]. We generated highly potent neu-
tralising JCPyV VP1-specific antibodies by recombinant
cloning from a PML patient who successfully controlled
the viral infection after IRIS and recovered from PML
[135]. These human-derived antibodies exhibited exquis-
ite specificity and high affinity towards JCPyV, neutralised
the JCPyV infection in vitro and showed cross-reactivity
against the most common PML-causing JCPyV variants,
and represent promising candidates for the development of
a passive immunisation of PML patients. Similar work was
also successfully carried out in Ebola survivors [128, 129].
Adequate brain exposure to antibodies would be expected,
as observed for other human monoclonal antibodies in de-
velopment for CNS indications [140]. Passive immunisa-
tion appears to be a promising approach, in particular for
PML related to HIV, transplantation or immunosuppres-
sive drug therapy patients, where immediate immune re-
constitution is not possible.
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Active and passive immunisation approaches for the pro-
phylactic and therapeutic treatment of PML are sum-
marised in figure 2.
Conclusion
PML remains an untreatable and often fatal opportunistic
infection of the brain. Its resurgence with the increasing
use of novel potent immunomodulatory treatments for a
variety of diseases makes the development of prophylactic
and therapeutic strategies for PML a high unmet medical
need. Current data suggest that all three arms of the adap-
tive immune system, – virus-specific CD4+ and CD8+ T
cells and virus-specific antibodies – are important for con-
trolling infection with JCPyV and also for resolving PML
once it has developed. Active therapeutic vaccination, as
well as high affinity, cross-neutralising, anti-JCPyV
VP1-specific human monoclonal antibodies are promising
approaches to the development of an effective treatment
and prophylaxis of PML.
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